Emerging Postoperative Pain therapies such as VVZ-149 Injections, IV Tramadol, TLC590, and others are expected to boost the Postoperative Pain market.
DelveInsight’s “Postoperative Pain – Market Insights, Epidemiology, and Market Forecast-2034″ report delivers an in-depth understanding of the Postoperative Pain, historical and forecasted epidemiology as well as the Postoperative Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key highlights from the postoperative pain market:
The postoperative pain Drugs Market is poised for growth, driven by rising demand for pain relief medications and medical devices. Globally, the increasing number of surgeries among cancer patients is a significant factor propelling market expansion. Additionally, the need for effective postoperative pain management is amplified by the slower recovery rates typically observed in elderly individuals and those undergoing medical procedures.
Moreover, the surge in postoperative pain instances can be linked to a range of factors, with the influence of the COVID-19 pandemic being significant among them. The interruption in healthcare services and the postponement of surgeries during the pandemic resulted in a backlog of procedures.
Despite advancements in acute pain physiology, the development of new opioid and non-opioid analgesics, innovative drug delivery methods, and the widespread adoption of minimally invasive surgical techniques aimed at reducing pain, postoperative pain remains a persistent challenge for healthcare practitioners.
OLINVYK (oliceridine), a new G protein-biased (selective) mu-opioid receptor (MOR) ligand, has received approval in the US for managing acute pain in adults. It is eligible for reimbursement in both inpatient and outpatient settings until permanent codes are established.
The majority of approved medications are designed for adult use, presenting a significant opportunity for pharmaceutical companies to create drugs with enhanced efficacy and reduced side effects specifically tailored for the younger demographic. Furthermore, the increasing awareness of multimodal analgesia among both clinicians and patients represents a significant advantage in addressing postoperative pain.
Some of the key facts of the Postoperative Pain Market Report:
1. As per our analysis, the total number of cases in 2020 of postoperative pain in the 7MM was ~66,426,000 which is expected to increase at a significant rate.
2. In 2020, the total number of patients with postoperative pain in the US was ~40,618,000. The majority of the cases were of moderated type (44.50%).
4. In EU5, the number of cases was highest in Germany followed by France and the United Kingdom while the least number of cases were reported in Spain during the study period (2020–2034).
5. In 2020, Japan reported 1,22,49,558 cases of Postoperative pain, out of which there were ~54,51,000 cases of moderate type.
6. As per DelveInsight’s assessment, globally, about 45+ key pharma and biotech companies are working on 50+ pipeline drugs in the Postoperative Pain therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
Key benefits of the Postoperative Pain market report:
1. Postoperative Pain market report covers a descriptive overview and comprehensive insight of the Postoperative Pain Epidemiology and Postoperative Pain market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Postoperative Pain market report provides insights on the current and emerging therapies.
3. Postoperative Pain market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Postoperative Pain market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Postoperative Pain market.
Got queries? Click here to know more about the Postoperative Pain Market Landscape.
Postoperative Pain Overview
Postoperative pain is a temporary increase in baseline pain that typically follows surgery. It can range from mild discomfort to more intense pain and generally resolves within days to months as the body heals. This pain is often linked to soft tissue damage, such as an ankle sprain or paper cut. While the pain is usually short-lived, it gradually diminishes as the affected tissues recover.
The experience of postoperative pain varies greatly from patient to patient and is influenced by a combination of factors. These include preoperative psychological and pharmaceutical preparation, the type of anesthesia used, pain management strategies before and after surgery, the occurrence of surgical complications, and the quality of postoperative care. Additional factors that can impact the intensity, duration, and quality of postoperative pain include the location and nature of the surgical procedure, the size and extent of the incision, the degree of surgical trauma, and the patient’s overall physical and mental state, including their personal approach to managing pain.
The management of postoperative pain typically involves a multimodal approach designed to optimize pain relief while minimizing potential side effects and complications. Although most surgical patients experience acute postoperative pain, studies suggest that fewer than half report satisfactory pain relief following surgery. This treatment approach combines both pharmacological and non-pharmacological interventions to offer more comprehensive pain management.
Pharmacological therapies include a range of analgesics, such as opioids, NSAIDs, acetaminophen, corticosteroids, and anesthetics. Additional medications like benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, GABA agonists, and cannabinoids are also used in acute pain management. On the other hand, non-pharmacological approaches involve therapies such as acupuncture, cognitive behavioral therapy (CBT), mindfulness-based stress reduction (MBSR), chiropractic manipulation, physical therapy, transcutaneous electrical nerve stimulation (TENS), massage, exercise, and other complementary and alternative medicine (CAM) treatments. Together, these interventions form a comprehensive strategy known as multimodal analgesia.
Opioids are a widely used class of drugs for managing postoperative pain, including fentanyl, hydromorphone, morphine, oxycodone, oxymorphone, and tramadol. Commonly prescribed opioids in pill form include oxycodone, and approved options for acute pain management include Zalviso, OLINVYK (Olinvo), Dzuveo (Dsuvia), Nucynta, and DepoDur.
Prescription data shows that opioids, along with NSAIDs, corticosteroids, and anesthetics, are frequently prescribed for postoperative pain. However, there is growing concern, particularly in the U.S., about the increasing reliance on opioids for pain management, which has contributed to the ongoing opioid misuse epidemic. A key driver of opioid misuse is the frequent prescription of opioids for severe pain following surgery or acute injuries. In contrast, opioids are less commonly prescribed in countries like Japan.
In the U.S., modifiable risk factors for persistent opioid use after surgery include the use of modified-release opioids, prolonged initial prescription durations, and repeated prescriptions. The misuse of opioids also remains a significant issue in the UK, where recent research has shown a link between prolonged opioid use and surgical procedures.
Major medical organizations, including the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists Committee on Regional Anesthesia, strongly recommend that clinicians incorporate paracetamol (acetaminophen) or NSAIDs into multimodal analgesic regimens for both adult and pediatric patients, unless contraindicated. This recommendation is supported by extensive evidence, reinforcing the value of non-opioid therapies in managing postoperative pain effectively and safely.
Postoperative Pain Market
The current postoperative pain treatment market is characterized by a variety of approaches, which can be broadly classified into pharmacological and non-pharmacological therapies. Pharmacological treatments include a range of analgesics, divided into categories such as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, corticosteroids, and anesthetics. In addition to these, benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric acid (GABA) agonists, and cannabinoids are also used to manage acute pain. On the other hand, non-pharmacological therapies encompass methods like acupuncture, cognitive behavioral therapy (CBT), mindfulness-based stress reduction (MBSR), chiropractic manipulation, physical therapy, transcutaneous electrical nerve stimulation (TENS), massage therapy, exercise, and other complementary and alternative medicine (CAM) treatments. Together, these therapies are part of a comprehensive approach known as multimodal analgesia, which combines different treatment methods to optimize pain relief and minimize side effects.
In recent years, significant changes have occurred in the postoperative pain management market. Traditionally, opioids like fentanyl, hydromorphone, and morphine were considered the gold standard for managing acute postoperative pain. However, these are increasingly being replaced by more beneficial and sustainable approaches, particularly multimodal analgesia. This shift has gained momentum as the benefits of combining various treatments to enhance pain relief while reducing reliance on opioids become clearer.
NSAIDs have emerged as a popular choice in postoperative pain management due to their effectiveness in reducing pain following surgery. Additionally, NSAIDs have been shown to reduce opioid consumption by up to 50%, provide superior analgesia when used alongside opioids, and are often recommended as first-line treatments for mild to moderate pain. However, NSAIDs are not without their potential side effects, particularly with long-term use. Other drugs commonly included in postoperative pain management include Exparel, acetaminophen, tramadol, gabapentinoids like gabapentin and pregabalin, and ibuprofen. These alternatives and adjuncts to opioids offer promising options for improving pain management outcomes in the postoperative setting.
Postoperative Pain Market Outlook
Effective pain management is essential for patients undergoing surgery, as it plays a crucial role in recovery and is increasingly recognized as a key indicator of postoperative quality. The goal of postoperative pain management is to alleviate discomfort with minimal side effects, but studies show that less than half of surgical patients experience satisfactory pain relief following their procedures.
Although awareness of the benefits of multimodal pain management has been growing, opioid monotherapy still remains the cornerstone of post-surgical pain treatment. Opioids administered through patient-controlled analgesia (PCA) provide systemic relief for moderate-to-severe postoperative pain. To enhance pain relief and reduce reliance on opioids, analgesics with different mechanisms of action and receptor targets are often combined, producing additive or even synergistic effects. Nonopioid analgesic regimens may include paracetamol (acetaminophen), NSAIDs (including cyclooxygenase inhibitors), alpha-2 agonists (such as clonidine and dexmedetomidine), gabapentin, pregabalin, ketamine, lignocaine infusions, peripheral nerve blocks, local anesthetic wound infiltration, and continuous wound infusion techniques.
The postoperative pain market is segmented by drug class (including opioids, NSAIDs, COX-2 inhibitors, and local anesthetics), route of administration (such as injectable, oral, topical, and other methods), and distribution channels (hospital and retail pharmacies, among others). As new therapies are expected to launch and patient screening and treatment integration improve, there is an opportunity for further innovation in pain management. This progress is expected to drive the development of more effective treatment options, as well as increase awareness about the benefits of comprehensive pain management.
In terms of market segmentation, the current Postoperative Pain Drugs Market includes off-label therapies, such as bronchodilators, diuretics, antibiotics, steroids, and others. These segments are crucial components of the overall treatment landscape and will be part of the forecasted growth in the coming years.
Postoperative Pain Pipeline Therapies and Key Companies
• ACP-044: ACADIA Pharmaceuticals
• CAM2048: Camurus
• CYT-1010: Cytogel Pharma
• DEXTENZA (dexamethasone): Ocular Therapeutix
• Qutenza: Grunenthal
• ST 2427: SiteOne Therapeutics
• SVT-15473 (clobetasol propionate ophthalmic nanoemulsion 0.05%): Salvat Laboratories
• TLC590: Taiwan Liposome Company
• VVZ-149: Vivozon
• ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics
To know more about the key postoperative pain pharma players in the market, visit postoperative pain therapeutics landscape.
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Postoperative Pain Patient Share (%) Overview at a Glance
5. Postoperative Pain Market Overview at a Glance
6. Postoperative Pain Disease Background and Overview
7. Postoperative Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Postoperative Pain
9. Postoperative Pain Current Treatment and Medical Practices
10. Unmet Needs
11. Postoperative Pain Emerging Therapies
12. Postoperative Pain Market Outlook
13. Country-Wise Postoperative Pain Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Postoperative Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Postoperative Pain Market Outlook 2034.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
